Patents by Inventor Douglas C. Behenna
Douglas C. Behenna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250206744Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.Type: ApplicationFiled: December 9, 2024Publication date: June 26, 2025Applicant: Janssen Pharmaceutica NVInventors: Steven D. Goldberg, Douglas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Brock T. Shireman, Alexander E. Valdes, Jennifer D. Venable, Dongpei Wu, Xiaohua Xue
-
Publication number: 20250122181Abstract: The present application discloses compounds having the following formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and X are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.Type: ApplicationFiled: September 26, 2022Publication date: April 17, 2025Applicant: Janssen Pharmaceutica NVInventors: Steven D. Goldberg, Douglas C. Behenna, Steven A. Loskot, Stefan J. McCarver, Timothy B. Rhorer, Kristin G. Song, Alexander E. Valdes, Craig R. Woods, Xiahua Xue, Brock T. Shireman, Virginia M. Tanis, Deane Gordan
-
Publication number: 20250109137Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.Type: ApplicationFiled: October 4, 2024Publication date: April 3, 2025Applicant: Janssen Pharmaceutica NVInventors: Steven D. Goldberg, Douglas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Timothy B. Rhorer, Kristen Song, Alexander E. Valdes, Dongpei Wu, Xiaohua Xue
-
Patent number: 12215111Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.Type: GrantFiled: September 26, 2022Date of Patent: February 4, 2025Assignee: Janssen Pharmaceutica NVInventors: Steven D. Goldberg, Douglas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Brock T. Shireman, Alexander E. Valdes, Jennifer D. Venable, Dongpei Wu
-
Publication number: 20240376085Abstract: The present application discloses compounds of Formula (I): (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.Type: ApplicationFiled: September 26, 2022Publication date: November 14, 2024Applicant: Janssen Pharmaceutica NVInventors: Charlotte Pooley Deckhut, Douglas C. Behenna, Scott Bembenek, Steven D. Goldberg, Paul F. Jackson, John Keith, Steven A. Loskot, Connor Martin, Stefan McCarver, Steven P. Meduna, Timothy B. Rhorer, Amy Y. Shih, Virginia M. Tanis, Craig R. Woods, Xiaohua Xue
-
Publication number: 20230147458Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.Type: ApplicationFiled: September 26, 2022Publication date: May 11, 2023Inventors: Steven D. Goldberg, Douglas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Brock T. Shireman, Alexander E. Valdes, Jennifer D. Venable, Dongpei Wu, Xiaohua Xue
-
Publication number: 20230098847Abstract: The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.Type: ApplicationFiled: July 18, 2022Publication date: March 30, 2023Inventors: Brian M. Stoltz, Scott C. Virgil, David E. White, Taiga Yurino, Yiyang Liu, Douglas C. Behenna, Douglas Duquette, Christian Eidamshaus
-
Patent number: 11390585Abstract: The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.Type: GrantFiled: February 1, 2021Date of Patent: July 19, 2022Assignee: California Institute of TechnologyInventors: Brian M. Stoltz, Scott C. Virgil, David E. White, Taiga Yurino, Yiyang Liu, Douglas C. Behenna, Douglas Duquette, Christian Eidamshaus
-
Publication number: 20210155592Abstract: The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.Type: ApplicationFiled: February 1, 2021Publication date: May 27, 2021Inventors: Brian M. Stoltz, Scott C. Virgil, David E. White, Taiga Yurino, Yiyang Liu, Douglas C. Behenna, Douglas Duquette, Christian Eidamshaus
-
Patent number: 10906875Abstract: The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.Type: GrantFiled: May 31, 2019Date of Patent: February 2, 2021Assignee: California Institute of TechnologyInventors: Brian M. Stoltz, Scott C. Virgil, David E. White, Taiga Yurino, Yiyang Liu, Douglas C. Behenna, Douglas Duquette, Christian Eidamshaus
-
Publication number: 20200157049Abstract: The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.Type: ApplicationFiled: May 31, 2019Publication date: May 21, 2020Inventors: Brian M. Stoltz, Scott C. Virgil, David E. White, Taiga Yurino, Yiyang Liu, Douglas C. Behenna, Douglas Duquette, Christian Eidamshaus
-
Patent number: 10343996Abstract: The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.Type: GrantFiled: July 30, 2018Date of Patent: July 9, 2019Assignee: California Institute of TechnologyInventors: Brian M. Stoltz, Scott C. Virgil, David E. White, Taiga Yurino, Yiyang Liu, Douglas C. Behenna, Douglas Duquette, Christian Eidamshaus
-
Publication number: 20180339968Abstract: The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.Type: ApplicationFiled: July 30, 2018Publication date: November 29, 2018Inventors: Brian M. Stoltz, Scott C. Virgil, David E. White, Taiga Yurino, Yiyang Liu, Douglas C. Behenna, Douglas Duquette, Christian Eidamshaus
-
Patent number: 10035769Abstract: The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.Type: GrantFiled: December 1, 2016Date of Patent: July 31, 2018Assignee: California Institute of TechnologyInventors: Brian M. Stoltz, Scott C. Virgil, David E. White, Taiga Yurino, Yiyang Liu, Douglas C. Behenna, Douglas Duquette, Christian Eidamshaus
-
Publication number: 20170137382Abstract: The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.Type: ApplicationFiled: December 1, 2016Publication date: May 18, 2017Inventors: Brian M. Stoltz, Scott C Virgil, David E. White, Taiga Yurino, Yiyang Liu, Douglas C. Behenna, Douglas Duquette, Christian Eidamshaus
-
ENANTIOSELECTIVE SYNTHESIS OF DIALKYLATED N,O-HETEROCYCLES BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION
Publication number: 20160096810Abstract: This invention provides enantioenriched N,O-heterocyclic compounds with quaternary stereogenic centers and novel methods of preparing the compounds. Methods include the method for the preparation of a compound of formula (I): comprising treating a compound of formula (II): with a transition metal catalyst under alkylation conditions.Type: ApplicationFiled: October 7, 2015Publication date: April 7, 2016Inventors: Brian M. Stoltz, Yoshitaka Numajiri, Douglas C. Behenna -
Patent number: 8822679Abstract: A compound useful as a building block for the manufacture of various compounds is represented by Formula A or D. In Formula A and D, z is 0 or 1; Q is a heteroatom; R1 through R11 and Ra through Rf are each independently hydrogen, a substituted or unsubstituted hydrocarbyl group, a substituted or unsubstituted heteroatom containing hydrocarbyl group, or a functional group; d, e and f are each independently 0 or greater; each of A, B and D is independently a carbon atom or a heteroatom; and two or more of R1 though R11, Ra through Rf and Y optionally combine to form a ring. In some embodiments, R8 and R9 combine to form a carbonyl group. In some embodiments, R2 and Y combine to form a ring with the Q atom. In some embodiments, the ring includes at least one double bond.Type: GrantFiled: June 22, 2012Date of Patent: September 2, 2014Assignee: California Institute of TechnologyInventors: Brian M Stoltz, Scott C. Virgil, David E White, Taiga Yurino, Yiyang Liu, Douglas C Behenna, Douglas Duquette, Christian Eidamshaus
-
Publication number: 20130267699Abstract: The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.Type: ApplicationFiled: March 12, 2013Publication date: October 10, 2013Inventors: Brian M. Stoltz, Scott C. Virgil, David E. White, Taiga Yurino, Yiyang Liu, Douglas C. Behenna, Douglas Duquette, Christian Eidamshaus
-
Publication number: 20130012701Abstract: A compound useful as a building block for the manufacture of various compounds is represented by Formula A or D. In Formula A and D, z is 0 or 1; Q is a heteroatom; R1 through R11 and Ra through Rf are each independently hydrogen, a substituted or unsubstituted hydrocarbyl group, a substituted or unsubstituted heteroatom containing hydrocarbyl group, or a functional group; d, e and f are each independently 0 or greater; each of A, B and D is independently a carbon atom or a heteroatom; and two or more of R1 though R11, Ra through Rf and Y optionally combine to form a ring. In some embodiments, R8 and R9 combine to form a carbonyl group. In some embodiments, R2 and Y combine to form a ring with the Q atom. In some embodiments, the ring includes at least one double bond.Type: ApplicationFiled: June 22, 2012Publication date: January 10, 2013Applicant: California Institute of TechnologyInventors: Brian M. Stoltz, Scott C. Virgil, David E. White, Taiga Yurino, Yiyang Liu, Douglas C. Behenna, Douglas Duquette, Christian Eidamshaus
-
Patent number: 7235698Abstract: Compounds containing a substituted or unsubstituted allyl group directly bound to a chiral carbon atom are prepared enantioselectively. Starting reactants are either chiral or achiral, and may or may not contain an attached allyloxycarbonyl group as a substituent. Chiral ligands are employed, along with transition metal catalysts. The methods of the invention are effective in providing enantioconvergent allylation of chiral molecules.Type: GrantFiled: August 29, 2005Date of Patent: June 26, 2007Assignee: California Institute of TechnologyInventors: Douglas C. Behenna, Brian M. Stoltz, Justin T. Mohr, Andrew M. Harned